Virax Biolabs’ Q2 2026 Investor Presentation: Next-Generation Diagnostics for Chronic Inflammation and Immune Dysfunction

The Virax Biolabs updated investor presentation for Q2 2026 has just been released. This deck provides an overview of our current clinical milestones and strategic roadmap for the coming months. You can review the full presentation below or download a copy for your records:


Q2 2026 Investor Presentation